Preemptive Strike With Bortezomib in Multiple Myeloma Patients

Stopped early · Phase 3

Conditions studied: Multiple Myeloma

In brief

To evaluate whether using the drug bortezomib at the start of remission will prevent relapse for a longer period of time.

Key facts

Study ID

NCT00657553

Run by

University of Arkansas

People needed

10

Starts

2008-02-01

Expected to finish

2009-01-01

Last updated by the study team

2017-11-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with multiple myeloma currently or previously enrolled on UARK 98-026 and currently event-free at the time of the evaluation.
• Performance status of 0-2 based of Southwest Oncology Group (SWOG) criteria
• Previously documented platelet count > 75,000/ul within a 35 days prior to enrollment
• Previously documented peripheral absolute neutrophil count >1,000/ul within 35 days prior to enrollment.
• Adequate renal function
• Signed informed consent
• Female subject is post-menopausal or willing to use acceptable birth control
• Male subjects agree to use acceptable method of contraceptive

You may not qualify if…

• Hypersensitivity to Bortezomib, boron, or mannitol
• Female subject is pregnant or breastfeeding
• Experienced myocardial infraction within 6 months prior to enrollment
• Received other investigational new drugs within 14 days before enrollment
• Received any anti-myeloma therapy within 14 days
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study
• Diagnosed or treated for another malignancy within 3 years of enrollment

Where it is running

• University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.